Patients who are having difficulty affording Schering- Plough medications can call the Schering-Plough Cares Patient Assistance Program at 1-800-656-9485 to see if they qualify for assistance. Or visit www.pparx.org for additional information.
Many legitimate providers of reliable health and medical
information, including FDA, other government agencies and consumer-oriented
medical organizations are taking advantage of the Web's popularity by offering
brochures and in-depth information on their Web sites. Material may be written
for the public as well as to industry and medical professionals. However, there
are problems such as (1) sites that contain fraudulent drug offerings, (2)
healthcare information that is incorrect or out of date and (3) site content
that has not been properly reviewed by medical authorities.
FDA Checklist for
Online Health Information
The FDA prepared a checklist of questions they recommend for
evaluating the reliability and credibility of healthcare information on the
Web:
Who maintains the site?
Is there an editorial board?
Does the site link to other sources of medical information?
When was the site last updated?
Does the site charge an access fee?
So how does the
CLARINEX® Web site measure
up?
Much of the content on the
CLARINEX® Web site is based on medical
manuscripts that have been peer reviewed and published in established medical
journals. This content was derived from the works of leaders in key allergy
organizations such as AAAAI (American Academy of Allergy, Asthma and
Immunology) and the ACAAI (American College of Allergy, Asthma and Immunology);
some of this was originally published in a major three-volume set called The
Allergy Report.
All content on the CLARINEX®
Web site is reviewed in detail by professionals whose job it is to ensure the
validity and reliability of the data. One major advantage for the public is
that because Schering develops and markets pharmaceutical products, the
regulations with regard to the type of information that can appear on a Web
site such as Clarinex.com are far more strict than Web sites and other
publications that are not associated with the pharmaceutical industry. You will
find no information that relates any of Schering's products to diseases or
medical problems that are not strictly identified in the FDA-approved package
insert for that product.
We are proud of the CLARINEX®
Web site and the medical information it has to offer. We hope you spend some
time learning as much as you can about your seasonal and year-round allergies.
We also urge you to speak with your doctor about any allergy symptoms,
questions regarding medication, and advice for your long-term
follow-up.
The CLARINEX® team also
welcomes your comments and suggestions, which you can send to us via email at
webmaster@clarinex.com.
The CLARINEX®
Team
CLARINEX®, a prescription medication, treats year-round allergy symptoms and ongoing hives of unknown cause, in adults and children 6 months and older, and seasonal allergy symptoms in patients 2 years and older. CLARINEX® 5 mg Tablets and 5 mg RediTabs® Tablets are approved for patients 12 years and older; CLARINEX® 2.5 mg RediTabs® Tablets are approved for patients 6 to 11 years; CLARINEX® Syrup is approved for patients 6 months and older.
Twice-daily CLARINEX-D® 12 HOUR Extended Release Tablets and once-daily CLARINEX-D® 24 HOUR Extended Release Tablets treat the symptoms of seasonal allergies, including nasal congestion, in patients 12 years and older.
IMPORTANT SAFETY INFORMATION CLARINEX® Tablets side effects in patients 12 years and older were similar to placebo and included sore throat, dry mouth, and fatigue for seasonal and year-round allergy patients, and headache, nausea, and fatigue for patients with ongoing hives of unknown cause.
CLARINEX® Syrup side effects in children 6 to 11 years were similar to placebo. For children 6 months to 5 years, syrup side effects varied by age and included fever, diarrhea, upper respiratory infection, irritability, and coughing.
Due to their pseudoephedrine component, CLARINEX-D® 12 HOUR Extended Release Tablets and CLARINEX-D® 24 HOUR Extended Release Tablets should not be taken by patients with narrow-angle glaucoma (abnormally high eye pressure), difficulty urinating, severe high blood pressure, or severe heart disease, or by patients who have taken a monoamine oxidase (MAO) inhibitor within the past fourteen (14) days. Patients with high blood pressure; diabetes; heart disease; increased intraocular pressure (eye pressure); thyroid, liver or kidney problems; or enlarged prostate should check with their healthcare provider before taking CLARINEX-D® 12 HOUR Extended Release Tablets or CLARINEX-D® 24 HOUR Extended Release Tablets.
Care should be used if CLARINEX-D® 12 HOUR Extended Release Tablets or CLARINEX-D® 24 HOUR Extended Release Tablets are taken with other antihistamines or decongestants because combined effects on the cardiovascular system may be harmful. The most commonly reported adverse events for CLARINEX-D® 12 HOUR Extended Release Tablets were insomnia, headache, dry mouth, fatigue, drowsiness, sore throat, and dizziness. The most commonly reported adverse events for CLARINEX-D® 24 HOUR Extended Release Tablets were dry mouth, headache, insomnia, fatigue, sore throat, and drowsiness.
Click here for important CLARINEX® Tablets/Syrup/RediTabs® Product Information. Click here for important CLARINEX-D® 12 HOUR Product Information. Click here for important CLARINEX-D® 24 HOUR Product Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Note: The information on this site is not intended to be a substitute for professional medical advice. If you have any questions about your treatment or medical condition, please consult your doctor or other qualified health care provider. This site is intended for use by U.S. residents.
